Deciphera Pharmaceuticals (DCPH) Prices 3.18M Share Common Offering at $55/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St eyes best day in a month as Anthropic's IPO filing propels AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazilās Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Britain will not join Canada-led defence bank initiativeĀ
- CAE agrees to sell Flightscape unit to SITA for $500 million
Deciphera Pharmaceuticals (DCPH) Announces FDA Acceptance of NDA and Priority Review for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
February 12, 2020 4:41 PM ESTDeciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its New Drug Application (NDA) seeking approval for ripretinib, the Companys investigational broad-spectrum KIT and PDGFR inhibitor, for the treatment of patients with... More
Deciphera Pharmaceuticals (DCPH) to Offer $250M in Stock
February 12, 2020 4:15 PM ESTDeciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) announced the commencement of a registered underwritten public offering of $250.0 million in shares of its common stock. In addition, Deciphera intends to grant the underwriters a 30-day option to purchase up to $37.5 million in shares of its... More



